Cancer immunotherapy using checkpoint blockade

Science, Год журнала: 2018, Номер 359(6382), С. 1350 - 1355

Опубликована: Март 22, 2018

The release of negative regulators immune activation (immune checkpoints) that limit antitumor responses has resulted in unprecedented rates long-lasting tumor patients with a variety cancers. This can be achieved by antibodies blocking the cytotoxic T lymphocyte–associated protein 4 (CTLA-4) or programmed cell death 1 (PD-1) pathway, either alone combination. main premise for inducing an response is preexistence cells were limited specific checkpoints. Most who have maintain disease control, yet one-third relapse. Mechanisms acquired resistance are currently poorly understood, but evidence points to alterations converge on antigen presentation and interferon-γ signaling pathways. New-generation combinatorial therapies may overcome mechanisms checkpoint therapy.

Язык: Английский

---

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

Cell, Год журнала: 2017, Номер 168(4), С. 707 - 723

Опубликована: Фев. 1, 2017

Язык: Английский

---

Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade

Cell Reports, Год журнала: 2017, Номер 18(1), С. 248 - 262

Опубликована: Янв. 1, 2017

The Cancer Genome Atlas revealed the genomic landscapes of human cancers. In parallel, immunotherapy is transforming treatment advanced Unfortunately, majority patients do not respond to immunotherapy, making identification predictive markers and mechanisms resistance an area intense research. To increase our understanding tumor-immune cell interactions, we characterized intratumoral immune cancer antigenomes from 20 solid cancers created Immunome (https://tcia.at/). Cellular characterization infiltrates showed that tumor genotypes determine immunophenotypes escape mechanisms. Using machine learning, identified determinants immunogenicity developed a scoring scheme for quantification termed immunophenoscore. immunophenoscore was superior predictor response anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) anti-programmed death protein 1 (anti-PD-1) antibodies in two independent validation cohorts. Our findings this resource may help inform facilitate development precision immuno-oncology.

Язык: Английский

---

Approaches to treat immune hot, altered and cold tumours with combination immunotherapies

Nature Reviews Drug Discovery, Год журнала: 2019, Номер 18(3), С. 197 - 218

Опубликована: Янв. 4, 2019

Язык: Английский

---

The immune contexture in cancer prognosis and treatment

Nature Reviews Clinical Oncology, Год журнала: 2017, Номер 14(12), С. 717 - 734

Опубликована: Июль 25, 2017

Язык: Английский

---

Regulation and Function of the PD-L1 Checkpoint

Immunity, Год журнала: 2018, Номер 48(3), С. 434 - 452

Опубликована: Март 1, 2018

Язык: Английский

---

Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment

Cancer Cell, Год журнала: 2017, Номер 32(1), С. 42 - 56.e6

Опубликована: Июль 1, 2017

Язык: Английский

---

A decade of immune-checkpoint inhibitors in cancer therapy

Nature Communications, Год журнала: 2020, Номер 11(1)

Опубликована: Июль 30, 2020

Immunotherapy using immune-checkpoint modulators revolutionizes the oncology field far beyond their remarkable clinical efficacy in some patients. It creates radical changes evaluation of treatment and toxicity with a more holistic vision patient cancer.

Язык: Английский

---

The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy

Nature reviews. Cancer, Год журнала: 2020, Номер 20(11), С. 662 - 680

Опубликована: Авг. 4, 2020

Язык: Английский

---

The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy

Cancer Cell, Год журнала: 2018, Номер 33(4), С. 570 - 580

Опубликована: Апрель 1, 2018

Язык: Английский

---